本研究旨在评估辅助化疗对I期胰腺导管腺癌患者生存的影响，并根据病理危险因素分层。对259例接受根治性切除的I期胰腺导管腺癌患者进行回顾性分析。根据神经周围和/或淋巴血管侵犯的存在，将患者分为有病理风险和无病理风险的组。进行子集 Kaplan-Meier 生存期和多变量分析以确定无复发生存期和总生存期。辅助化疗并未显着延长以下患者的无复发生存期 (P = .213)，但增加了总生存期 (P = .019)： I期胰腺导管腺癌。在亚组分析中，辅助化疗显着改善了有病理风险的患者 (n = 160) 的无复发生存期 (P = .037) 和总生存期 (P = .007)。然而，无病理风险的患者 (n = 99) 在辅助化疗后没有表现出无复发生存率 (P = .870) 和总生存率 (P = .413) 的提高。子集多变量分析表明，辅助化疗对于有病理风险的患者来说是一个独立的有利预后因素，但对于没有病理风险的患者则不然。I 期胰腺导管腺癌的辅助化疗可能会特别为有病理风险的患者提供生存获益。版权所有 © 2024 Elsevier Inc 。 版权所有。

This study aimed to evaluate the impact of adjuvant chemotherapy on survival in patients with stage I pancreatic ductal adenocarcinoma, stratified according to pathologic risk factors.A total of 259 patients with stage I pancreatic ductal adenocarcinoma who underwent radical resection were retrospectively analyzed. The patients were categorized into groups with and without pathologic risk based on the presence of perineural and/or lymphovascular invasion. Subset Kaplan-Meier survival and multivariate analyses were performed to determine the recurrence-free survival and overall survival.Adjuvant chemotherapy did not significantly prolong recurrence-free survival (P = .213) but increased overall survival (P = .019) in patients with stage I pancreatic ductal adenocarcinoma. In subgroup analysis, adjuvant chemotherapy significantly improved recurrence-free survival (P = .037) and overall survival (P = .007) in patients with pathologic risk (n = 160). However, patients without pathologic risk (n = 99) showed no enhancement of recurrence-free survival (P = .870) and overall survival (P = .413) after adjuvant chemotherapy. Subset multivariate analyses indicated that adjuvant chemotherapy was an independent favorable prognostic factor in patients with pathologic risk but not in those without pathologic risk.Adjuvant chemotherapy for stage I pancreatic ductal adenocarcinoma may provide survival benefits specifically to patients with pathologic risk.Copyright © 2024 Elsevier Inc. All rights reserved.